文献速递皮肤感染自身免疫性与大疱性皮肤病

丙型肝炎病毒及其皮肤表现:直接抗病毒药物时代的治疗

Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-03-29

综述回顾HCV相关皮肤病(混合冷球蛋白血症、扁平苔藓、迟发性皮肤卟啉病、坏死松解性肢端红斑)在全口服DAA时代的治疗证据。DAA及持续病毒学应答对混合冷球蛋白血症的皮肤症状改善证据最多,但现有研究样本小、回顾性、缺乏对照。建议对上述皮肤病患者考虑筛查HCV。

要点

  • HCV相关皮肤病包括混合冷球蛋白血症、扁平苔藓、迟发性皮肤卟啉病和坏死松解性肢端红斑。
  • DAA治疗及获得SVR对混合冷球蛋白血症的皮肤症状改善证据最多。
  • 对混合冷球蛋白血症、扁平苔藓、迟发性皮肤卟啉病和坏死松解性肢端红斑患者应考虑筛查HCV。

核心结论

  • 全口服DAA时代,治疗 underlying HCV 对HCV相关皮肤病具有潜在获益,但皮肤表现方面的数据仍有限。

研究设计与样本

  • 综述,检索PubMed和EMBASE英文文献,检索词包括hepatitis C、direct acting antivirals、cutaneous、mixed cryoglobulinemia等。

主要发现

  • DAA治疗HCV合并皮肤副作用患者的数据有限。
  • 混合冷球蛋白血症研究数据最多,多项研究提示DAA及获得SVR可改善皮肤症状。
  • 新旧方案研究均受样本量小、回顾性设计、缺乏合适对照和研究方案差异大限制。

关键数值与推荐

  • 对几乎全部HCV患者推荐治疗,新药提供更优给药方案和副作用特征。
  • 混合冷球蛋白血症、扁平苔藓、迟发性皮肤卟啉病和坏死松解性肢端红斑与HCV强相关,应考虑筛查HCV。

临床怎么用

  • 皮肤科医生应了解DAA治疗选择及其在HCV相关皮肤病中的效用。
  • 对混合冷球蛋白血症、扁平苔藓、迟发性皮肤卟啉病和坏死松解性肢端红斑患者考虑筛查HCV。

局限性

  • DAA用于HCV感染伴皮肤副作用患者的数据有限。
  • 现有研究样本量小、回顾性、缺乏合适对照、研究方案差异大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New all-oral direct-acting antivirals (DAA) have changed the hepatitis C virus (HCV) treatment landscape. Given that dermatologists frequently encounter HCV-infected patients, knowledge of the current treatment options and their utility in treating HCV-associated dermatologic disorders is important. In addition to highlighting the new treatment options, we review four classically HCV-associated dermatologic disorders - mixed cryoglobulinaemia (MC), lichen planus (LP), porphyria cutanea tarda (PCT) and necrolytic acral erythema (NAE) - and examine the role for all-oral direct-acting antiviral (DAA) regimens in their treatment. A literature search of English-language publications was conducted of the PubMed and EMBASE databases using search terms including 'hepatitis C', 'direct acting antivirals', 'cutaneous', 'mixed cryoglobulinemia', 'necrolytic acral erythema', 'lichen planus', 'porphyria cutanea tarda', 'rash', as well as specific drug names, related terms and abbreviations. Currently, limited data exist on the use of DAAs in HCV-infected patients with cutaneous side-effects, although treatment of the underlying HCV is now recommended for nearly all patients, with the new drugs offering much-improved dosage schedules and side-effect profiles. The most data exist for MC, in which several studies suggest that DAAs and achievement of sustained virologic response (SVR) improve cutaneous symptoms. Studies of both older and newer regimens are limited by their small size, retrospective nature, lack of appropriate controls and wide variability in study protocols. Given the strong association, screening for HCV should be considered in patients with MC, LP, PCT and NAE.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Wiznia LE, Laird ME, Franks AG, et al. Hepatitis C virus and its cutaneous manifestations: treatment in the direct-acting antiviral era. J Eur Acad Dermatol Venereol. 2017. PMID: 28252812. doi:10.1111/jdv.14186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。